Good news. Stock up $1+ on down day (from yahoo)
Home - Yahoo! - Help
--------------------------------------------------------------------------------
Click Here!
[ Business | US Market | By Industry | IPO | AP | S&P | International | PRNews | BizWire | CCN ]
--------------------------------------------------------------------------------
Related Quotes
AVGN
12 5/16
+15/16
delayed 20 mins - disclaimer
Tuesday September 21, 6:00 am Eastern Time
Company Press Release
SOURCE: Avigen, Inc.
Avigen Receives a Broad Patent for AAV Cancer Gene Therapy and a Patent For Adenovirus-Free AAV Production
ALAMEDA, Calif., Sept. 21 /PRNewswire/ -- Avigen, Inc. (Nasdaq: AVGN - news) today announced the issuance of U.S. Patent No. 5,952,221 to Avigen covering recombinant adeno-associated virus (AAV) vectors carrying therapeutic genes for the treatment of cancer, including genes encoding suicide proteins, antiangiogenic factors, interferons, lymphokines, tumor suppressors and growth factors. The patent is for a two gene system with one gene encoding a therapeutic protein and the other a ''gene switch'' which allows the therapy to be terminated. Scientists from Avigen developed the research underlying the patent.
''This is yet another example of Avigen's large and diverse AAV patent estate borne from research conducted at Avigen,'' said Avigen's President and CEO, John Monahan, Ph.D. ''We believe that this is a significant patent because it encompasses all types of cancers, including lung, colon, breast, prostate, liver, and glioma,'' he said.
One of the current obstacles for certain gene therapy applications is the ability to regulate the expression of the gene product or to terminate therapy once the therapy is completed. For hemophilia A and hemophilia B, Avigen's lead programs, gene regulation is not required because the therapy calls for continuous life-long expression of high levels of protein. For cancer, however, it is often imperative that the gene therapy be terminated or modulated after some time due either to the toxicity of the therapeutic agent or because the tumor has regressed. Avigen scientists addressed this problem by inserting two genes into a single AAV vector. One gene encodes a therapeutic protein such as Beta-interferon (Beta-INF), Angiostatin®, Endostatin(TM), interleukin-2 (IL-2), p53, or granulocyte-macrophage colony stimulating factor (GM-CSF). These genes are typically inserted into a small fraction of the patient's tumor cells via gene therapy to stimulate an anti-tumor effect. The other gene is a ''switch'' which terminates the therapy in response to a pharmaceutical compound given to the patient. These genes are known as suicide genes because they will kill any cancer cell containing the suicide gene in response to a pro-drug. For example, the suicide gene thymidine kinase (TK) kills cancer cells in response to the pro-drug ganciclovir by shutting down DNA synthesis. In this way, the therapy can be allowed to continue as long as necessary, yet terminated to avoid long term toxicity.
Using this approach, Avigen and collaborators at the Nagoya University School of Medicine in Japan have employed AAV to transfer the thymidine kinase (TK) gene in combination with interleukin-2 to experimental gliomas in mice. Interleukin-2 is a cytokine which increases the host's immune response to the malignancy. Following six days of ganciclovir administration, histopathology results showed that tumors treated with the AAV vector were an average of eleven times (11X) smaller than the untreated controls. Similar results were observed when the gene encoding Beta-interferon was used.
Avigen was also granted U.S. Patent No. 5,945,335 covering compositions and methods for making AAV free of helper-viruses such as adenovirus. Using the adenovirus-free technology in the patent, undesirable adenoviral protein can be eliminated from the manufacturing process without compromising product yields.
''Avigen now has one of the largest AAV-related patent estates,'' said Kenneth G. Chahine, Ph.D., JD, Vice President of Business Development and Chief Patent Counsel. ''These patents encompass numerous significant aspects of AAV, including manufacturing, tissue administration, vectors, and disease treatment,'' he added.
Based in the San Francisco Bay Area, Avigen, Inc. is a biotechnology company involved in the development of gene therapy products derived from adeno-associated virus for the treatment of inherited and acquired diseases. The Company's proposed gene therapy products are designed for in vivo administration to achieve the production of therapeutic proteins within the body.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this press release, as well as other risks detailed from time to time in documents filed by Avigen with the SEC, including the report on Form 10-K for the year ended June 30, 1998. In particular, the foregoing discussion of the effect of patents issued involves risks and uncertainty, including the risks: that third parties may be successful in challenging the patents; or that new technologies will be developed that are superior in treating the diseases targeted by the Company. In addition, the statements above regarding the potential for gene therapy using AAV for treating humans with inherited or acquired disorders is subject, in addition to the above, to the following risks and uncertainties: success of gene therapy in animal models does not guarantee that the same results will be obtained with humans; and other risks and uncertainties inherent in the development of gene therapy products.
NOTE: Angiostatin® and Endostatin(TM) are trademarks of EntreMed.
SOURCE: Avigen, Inc.
--------------------------------------------------------------------------------
More Quotes and News: Avigen Inc (Nasdaq:AVGN - news)
Related News Categories: biotech, medical/pharmaceutical
--------------------------------------------------------------------------------
Help
--------------------------------------------------------------------------------
Copyright © 1999 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
See our Important Disclaimers and Legal Information.
Questions or Comments? |
